QCLSNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Q/C TECHNOLOGIES, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$0.50−0.04 (-7.10%)
Close on Oct 19, 2026
- Market cap
- $4.12M
- P/E (TTM)
- –
- Dividend yield
- –
Q/C TECHNOLOGIES, INC. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| Product Revenue [Member] | – | – | – | – | $1.67M | $3.35M | – | – | – | – |
| License Fees [Member] | – | – | – | – | – | $50.00K | – | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| People's Republic of China [Member] | – | – | – | – | – | $502.13K | $503.00K | $37.51K | – | – |
| United States [Member] | – | – | – | – | – | $2.68M | $2.33M | $1.58M | – | – |
| Rest of World [Member] | – | – | – | $17.50K | $88.81K | $173.03K | $127.19K | $498.45K | – | – |
| United States | – | – | – | $1.56M | $1.58M | $2.68M | – | – | – | – |
From the segment and revenue-disaggregation notes of Q/C Technologies's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.